A Randomized Phase II Study of Adebrelimab in Combination with Chemotherapy with or Without Bevacizumab Neoadjuvant Therapy for Resectable Non-Squamous Non-Small Cell Lung Cancer
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This is a prospective, multicenter, randomized, uncontrolled Phase II study to assess the efficacy and safety of adebrelimab in combination with chemotherapy with or without bevacizumab for the treatment of resectable Stage II-IIIB (T3N2) NSQ-NSCLC and to explore biomarkers associated with efficacy.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:
• Resectable NSQ NSCLC
• Age 18-65 years
• male or female
• ECOG 0-1
• Subjects have not received surgery, chemotherapy, radiotherapy and biological treatment of treatment-naive non-squamous non-small cell lung cancer
• Subjects must have adequate pulmonary function for the intended pneumonectomy;
Locations
Other Locations
China
Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University
RECRUITING
Guangzhou
Contact Information
Primary
Jianxing He
jianxing.he@gmail.com
+86-20-83062807
Time Frame
Start Date: 2024-09-24
Estimated Completion Date: 2029-12-31
Participants
Target number of participants: 60
Treatments
Experimental: four-drug combination group
PD-L1 inhibitor with chemotherapy with Antiangiogenic therapy for neoadjuvant therapy
Experimental: three-drug combination group
PD-L1 inhibitor with chemotherapy for neoadjuvant therapy
Related Therapeutic Areas
Sponsors
Leads: The First Affiliated Hospital of Guangzhou Medical University